Laboratory Corp of America Holdings Stock News

Investors are optimistic about LabCorp (LH) backed by strength in its Drug Development business.

In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, autoimmune and liver disease as well as cell and gene therapy.

Laboratory Corporation of America Holdings (NYSE:LH ) Q4 2022 Earnings Conference Call February 16, 2023 9:00 AM ET Company Participants Chas Cook - Vice President of Investor Relations Adam Schechter

The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.

Shares of Labcorp LH, +1.79% were down about 2.9% in premarket trading on Thursday after the diagnostics company reported lower-than-expected revenue in the fourth quarter of 2022. Labcorp had earning

Labcorp LH, -0.52% said Thursday that it plans to spin off its clinical development business into a publicly traded clinical research organization, or CRO, in mid-2023. The name of the planned spin-of

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Labcorp is a strong player in the diagnostics space, with a network of 2,000 patient service centers. It has a long growth runway as its efficient scale makes it appealing for hospitals to outsource t

BURLINGTON, N.C.--( BUSINESS WIRE )--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.

LabCorp continues to rate as a buy following its Q3 numbers, despite a large pullback in Covid-19 revenue. Offsetting the distribution to its top-line, LH continues to compound capital and return on e

Laboratory Corporation of America Holdings (NYSE:LH ) Q3 2022 Earnings Conference Call October 27, 2022 9:00 AM ET Company Participants Chas Cook - VP, IR Adam Schechter - President, CEO & Chairman Gl